| Product Code: ETC12404622 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
The India haematologic malignancies treatment market import shipments displayed a steady expansion with a CAGR from 2020 to 2024 of 3.0. Notably, there was a significant acceleration in growth from 2023 to 2024, with a growth rate of 26.5, indicating a robust upward momentum and overall positive trend in market development.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 India Haematologic Malignancies Treatment Market Overview |
3.1 India Country Macro Economic Indicators |
3.2 India Haematologic Malignancies Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 India Haematologic Malignancies Treatment Market - Industry Life Cycle |
3.4 India Haematologic Malignancies Treatment Market - Porter's Five Forces |
3.5 India Haematologic Malignancies Treatment Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 India Haematologic Malignancies Treatment Market Revenues & Volume Share, By Cancer Type, 2021 & 2031F |
3.7 India Haematologic Malignancies Treatment Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 India Haematologic Malignancies Treatment Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 India Haematologic Malignancies Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 India Haematologic Malignancies Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of hematologic malignancies in India |
4.2.2 Technological advancements in treatment options |
4.2.3 Growing awareness about early diagnosis and treatment of hematologic malignancies |
4.3 Market Restraints |
4.3.1 High cost of treatment and medications |
4.3.2 Limited access to specialized healthcare facilities in certain regions of India |
4.3.3 Regulatory challenges and approval processes for new treatment options |
5 India Haematologic Malignancies Treatment Market Trends |
6 India Haematologic Malignancies Treatment Market, By Types |
6.1 India Haematologic Malignancies Treatment Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 India Haematologic Malignancies Treatment Market Revenues & Volume, By Drug Type, 2021 - 2031F |
6.1.3 India Haematologic Malignancies Treatment Market Revenues & Volume, By Chemotherapy, 2021 - 2031F |
6.1.4 India Haematologic Malignancies Treatment Market Revenues & Volume, By Targeted Therapy, 2021 - 2031F |
6.1.5 India Haematologic Malignancies Treatment Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.2 India Haematologic Malignancies Treatment Market, By Cancer Type |
6.2.1 Overview and Analysis |
6.2.2 India Haematologic Malignancies Treatment Market Revenues & Volume, By Leukemia, 2021 - 2031F |
6.2.3 India Haematologic Malignancies Treatment Market Revenues & Volume, By Lymphoma, 2021 - 2031F |
6.2.4 India Haematologic Malignancies Treatment Market Revenues & Volume, By Multiple Myeloma, 2021 - 2031F |
6.3 India Haematologic Malignancies Treatment Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 India Haematologic Malignancies Treatment Market Revenues & Volume, By IV, 2021 - 2031F |
6.3.3 India Haematologic Malignancies Treatment Market Revenues & Volume, By Oral, 2021 - 2031F |
6.3.4 India Haematologic Malignancies Treatment Market Revenues & Volume, By Injectable, 2021 - 2031F |
6.4 India Haematologic Malignancies Treatment Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 India Haematologic Malignancies Treatment Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.4.3 India Haematologic Malignancies Treatment Market Revenues & Volume, By Cancer Treatment Centers, 2021 - 2031F |
6.4.4 India Haematologic Malignancies Treatment Market Revenues & Volume, By Clinics, 2021 - 2031F |
6.5 India Haematologic Malignancies Treatment Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 India Haematologic Malignancies Treatment Market Revenues & Volume, By Specialty Pharmacies, 2021 - 2031F |
6.5.3 India Haematologic Malignancies Treatment Market Revenues & Volume, By Online Pharmacies, 2021 - 2031F |
6.5.4 India Haematologic Malignancies Treatment Market Revenues & Volume, By Direct Sales, 2021 - 2031F |
7 India Haematologic Malignancies Treatment Market Import-Export Trade Statistics |
7.1 India Haematologic Malignancies Treatment Market Export to Major Countries |
7.2 India Haematologic Malignancies Treatment Market Imports from Major Countries |
8 India Haematologic Malignancies Treatment Market Key Performance Indicators |
8.1 Average time from diagnosis to treatment initiation |
8.2 Patient survival rates post-treatment |
8.3 Adoption rate of novel therapies in the market |
9 India Haematologic Malignancies Treatment Market - Opportunity Assessment |
9.1 India Haematologic Malignancies Treatment Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 India Haematologic Malignancies Treatment Market Opportunity Assessment, By Cancer Type, 2021 & 2031F |
9.3 India Haematologic Malignancies Treatment Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 India Haematologic Malignancies Treatment Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 India Haematologic Malignancies Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 India Haematologic Malignancies Treatment Market - Competitive Landscape |
10.1 India Haematologic Malignancies Treatment Market Revenue Share, By Companies, 2024 |
10.2 India Haematologic Malignancies Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here